top of page

Newer obesity drugs

Updated: Sep 3, 2023


Newer obesity drugs

Obesity is a complex health condition that affects millions of people worldwide. While diet and exercise are the cornerstones of weight management, sometimes they are not enough. In such cases, newer obesity drugs like Ozempic, Wegovy, Saxenda, and Munjaro may be prescribed to aid in weight loss efforts.

Ozempic

Ozempic is a once-weekly injectable medication that helps to regulate blood sugar levels and reduce appetite. It works by mimicking the function of a hormone called glucagon-like peptide-1 (GLP-1), which is naturally produced in the body. Ozempic has been shown to help people lose an average of 12 pounds in just 26 weeks. However, it's important to note that Ozempic is not recommended for people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Wegovy

Wegovy is the newest obesity drug on the market, having been approved by the FDA in June 2021. It is also a once-weekly injectable medication that works similarly to Ozempic by mimicking GLP-1. Wegovy has been shown to help people lose an average of 15% of their body weight over a year, making it one of the most effective obesity drugs available. However, like Ozempic, it's not recommended for people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Saxenda

Saxenda is another injectable medication that works by regulating appetite. It was approved by the FDA in 2014 and has been shown to help people lose an average of 11 pounds in just 12 weeks. Saxenda is also a GLP-1 mimetic, but it is approved for people with a BMI of 30 or higher, as well as those with a BMI of 27 or higher who also have weight-related health conditions such as type 2 diabetes or high blood pressure.

Munjaro

Munjaro is a newer obesity drug that was approved by the FDA in May 2021. It is an oral medication that works by regulating appetite and reducing food intake. Munjaro has been shown to help people lose an average of 8.8 pounds in just 12 weeks. Unlike the other obesity drugs mentioned, Munjaro does not work by mimicking GLP-1. Instead, it acts on a different hormone in the body called melanocortin 4 receptor.

In conclusion, newer obesity drugs like Ozempic, Wegovy, Saxenda, and Munjaro can be helpful tools in weight management efforts. However, it's important to note that they are not a substitute for a healthy diet and regular exercise. Anyone considering these medications should talk to their healthcare provider to determine if they are a good fit for their individual needs and medical history.


Book your appointment in the outpatient clinic


Book your online consultation



12 views0 comments

Comments


bottom of page